More than a decade of work bonds Pfizer Inc. with Wachtell, Lipton, Rosen & Katz, and Mylan NV has ties with Cravath, Swaine & Moore that are just as deep.

So it’s no surprise that the drug makers tapped top partners from those Wall Street mainstays for their $48 billion deal to create a new generic drug giant.